Safety and Efficacy of Autologous, Adipose-Derived Mesenchymal Stem Cells in Patients with Rheumatoid Arthritis: A Phase I/IIa, Open-Label, Non-Randomized Pilot Trial

The authors performed a Phase I/IIa non-randomized, open-label study to evaluate the safety and efficacy of a single, intravenous infusion of autologous, adipose-derived MSCs over a period of 52 weeks, in patients with active rheumatoid arthritis.